IP Library Granted Patent US 12,064,599
Granted Patent B2
US 12,064,599 · App. 17/394,121 · Granted Aug 20, 2024

Management of insufficient hypoglycemia response

Inventors: Di Wu (Glendale, CA); Rebecca K. Gottlieb (Culver City, CA); Benyamin Grosman (Winnetka, CA); Anirban Roy (Agoura Hills, CA); Neha J. Parikh (West Hills, CA); Ohad Cohen (Kiryat Uno, IL)
Assignee: MEDTRONIC MINIMED, INC.
A61M5/1723A61B5/14532A61M5/14244G16H20/17G16H40/63G16H50/20G16H50/50A61M2005/14208A61M2205/50A61M2205/581A61M2205/583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,064,599
App. No.
17/394,121
Granted
Aug 20, 2024
Kind
B2
Abstract

Disclosed herein are techniques related to management of insufficient hypoglycemia response. In some embodiments, the techniques may involve obtaining an amount of insulin remaining in a body of a patient. The techniques may involve also obtaining a quantity of insulin needed by the patient within a future time period. Additionally, the techniques may involve identifying a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery. The condition may be identified based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period. Furthermore, the techniques may involve, responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.

Claims (27)

1. A system comprising:

one or more processors; and

one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:

obtaining, by a controller associated with an insulin delivery pump, an amount of insulin remaining in a body of a patient;

obtaining, by the controller, a quantity of insulin needed by the patient within a future time period;

based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period, identifying, by the controller, a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery; and

responsive to identifying the condition, causing, by the controller, performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.

2. The system of claim 1 , wherein the one or more processor-readable storage media further store instructions which, when executed by the one or more processors, cause performance, by the controller, of:

prior to identifying the condition, causing to suspend the basal insulin dosage delivery based on identifying a glucose trend in the patient toward the hypoglycemic range.

3. The system of claim 2 , wherein identifying the glucose trend in the patient comprises:

obtaining, by the controller, a plurality of glucose values;

calculating, by the controller, a glucose trend value based on computing a derivative of the plurality of glucose values; and

comparing, by the controller, the glucose trend value to a hypoglycemia threshold.

4. The system of claim 1 , wherein causing the performance of the action comprises communicating, by the controller, a command to a medication delivery device.

5. The system of claim 1 , wherein the action comprises delivering glucagon to the patient by a glucagon delivery system.

6. The system of claim 1 , wherein the action comprises presenting, via the insulin delivery pump, a recommendation to ingest a substance for increasing the patient's glucose level.

7. The system of claim 1 , wherein the amount of insulin remaining in the body is represented as an insulin-on-board (IOB) value corresponding to a quantity of insulin remaining in the patient following delivery of a bolus of insulin.

8. The system of claim 1 , wherein the quantity of insulin needed by the patient is calculated, by the controller, based on a total daily dose (TDD) value that is scaled by a factor to result in a value that is less than the TDD value, wherein the TDD value is a quantity of insulin to be delivered to the patient by the insulin delivery pump in a twenty-four hour period.

9. One or more processor-readable storage media storing instructions which, when executed by one or more processors, cause performance of:

obtaining, by a controller associated with an insulin delivery pump, an amount of insulin remaining in a body of a patient;

obtaining, by the controller, a quantity of insulin needed by the patient within a future time period;

based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period, identifying, by the controller, a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery; and

responsive to identifying the condition, causing, by the controller, performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.

10. The one or more processor-readable storage media of claim 9 , further storing instructions which, when executed by the one or more processors, cause performance of:

prior to identifying the condition, causing, by the controller, the insulin delivery pump to suspend the basal insulin dosage delivery based on identifying a glucose trend in the patient toward the hypoglycemic range.

11. The one or more processor-readable storage media of claim 9 , wherein the amount of insulin remaining in the body is represented as an insulin-on-board (IOB) value corresponding to a quantity of insulin remaining in the patient following delivery of a bolus of insulin.

12. The one or more processor-readable storage media of claim 9 , wherein the quantity of insulin needed by the patient is calculated, by the controller, based on a total daily dose (TDD) value that is scaled by a factor to result in a value that is less than the TDD value, wherein the TDD value is a quantity of insulin to be delivered to the patient by the insulin delivery pump in a twenty-four hour period.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: WU, DI; GOTTLIEB, REBECCA K.; GROSMAN, BENYAMIN; ROY, ANIRBAN; PARIKH, NEHA J.; COHEN, OHAD
To: MEDTRONIC MINIMED, INC.
Reel/Frame 059604/0361 →